Articles Tagged With:
-
Fecal Microbiota Transplantation: Patients Need No Convincing
Fecal microbiota transplantation appears effective in approximately 55-90% of patients with relapsing and refractory Clostridium difficile infection, and will prove a blessing to those who have been in a miserable cycle of recurrent disease.
-
Optimal Beta-blocker Dose Post-MI
Investigators from the Outcome of Beta-blocker Therapy After Myocardial Infarction (OBTAIN) study hypothesized that the higher the dose of beta-blocker the lower the mortality.
-
Metformin and Colorectal Cancer Risk
In a retrospective cohort study of patients with type 2 diabetes who had ≥ 1 adenoma detected at baseline colonoscopy and a repeat colonoscopy 1-10 years later, metformin use lowered the risk of subsequent adenomas after polypectomy.
-
Cardiovascular Events Associated with Masked Hypertension and White-coat Hypertension
Analysis from the Dallas Heart Study consisting of 3027 adults revealed that both white-coat hypertension and masked hypertension were independently associated with increased cardiovascular events, and, therefore, home blood pressure monitoring is recommended for U.S. adults, whether symptomatic or asymptomatic.
-
Patients using social media to lobby for access to investigational drugs
Social media campaigns have successfully pressured drug companies to approve some requests for investigational drugs for terminally ill patients under expanded access programs, but this raises significant ethical concerns, experts say.
-
Improve evaluation of IRB’s QI/QA processes
IRB offices need a systematic approach to quality improvement processes. They also should have a way to evaluate performance, subjecting the office to internal scrutiny, an IRB expert says.
-
IRB develops improved staff training for new hires
Leaders at one IRB decided to address concerns about new hire training through the development of a standardized training program for all new staff members.
-
IRB and IT collaboration can reap HRPP rewards
IRBs and researchers likely underestimate their vulnerability to data security breaches, which are a growing problem across the healthcare industry.
-
IRB members in their own words
Robert L. Klitzman, MD, interviewed some 45 IRB members for his new book, The Ethics Police? The following are some of the published comments by both IRB chairs and members on how they came to be on an IRB and their challenges in weighing the risks and benefits of human research.
-
The ethics police? New book issues challenge for change
Meet Robert L. Klitzman, MD, director of the Masters of Bioethics Program at Columbia University in New York City, and the author of The Ethics Police? The Struggle to Make Human Research Safe.